News - HanchorBio

HanchorBio to Present Five Clinical Abstracts at CSCO 2026

HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).

Sep 18, 2026

HanchorBio Partners with InSilicoTrials to Advance AI-Driven Clinical Development for HCB101

HanchorBio announced that it has entered into a strategic memorandum of understanding (MOU) and an initial statement of work with InSilicoTrials Technologies S.p.A.

Sep 16, 2026

HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026

HanchorBio announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.

Sep 14, 2026

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HanchorBio announced that the U.S. Food and Drug Administration (FDA) has cleared its HCB101 Single-Patient Expanded Access Protocol (HCB101- EA-001) as “safe to proceed”.

Sep 09, 2026

HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy

HanchorBio highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.

Sep 08, 2026

HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301

HanchorBio announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea.

Sep 07, 2026

HanchorBio Files U.S. IND for Second Trispecific Immunotherapy, HCB303

HanchorBio announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for HCB303. Developed using HanchorBio’s proprietary FBDB™ platform, HCB303 is the Company’s second trispecific immunotherapy program to reach clinical development.

Sep 03, 2026

HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference

HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.

Sep 01, 2026

HanchorBio Outlines Global Strategy for Gastric Cancer Immunotherapy as HCB101 Advances Beyond Phase 1

HanchorBio announced that Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented the Company’s vision for the next phase of gastric cancer immunotherapy at the Early Phase Clinical Trials: Innovation and Precision Medicine Forum in Taichung, Taiwan.

Aug 24, 2026

HanchorBio Advances Myeloid-Directed Therapeutics Strategy Beyond Oncology with HCB101 Clinical Progress and FBDB™ Platform Expansion

HanchorBio shared its latest clinical and research progress in myeloid-directed therapeutics at the 2026 Autumn Industry Trends and Corporate Forum hosted by Hua Nan Securities. The Company presented its development strategy centered on the proprietary FBDB™ multifunctional biologics platform and myeloid enhancer approach, highlighting clinical progress of HCB101 in solid tumors and the expansion of macrophage-directed biology into HCB206 for immune-mediated diseases.

Aug 21, 2026